Pharma giant Pfizer is injecting $600 million into its venture investment arm in a bid to ramp up its involvement in biotechnology and other emerging growth companies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.